Real-world efficacy of postoperative radiotherapy with a moderate dose-escalation for phyllodes tumors of the breast [0.03%]
乳腺叶状肿瘤术后调强放疗的疗效分析
Beatriz Álvarez,Angel Montero,Raquel Ciérvide et al.
Beatriz Álvarez et al.
Background: Phyllodes tumors are rare breast tumors comprising less than 1% of cases, categorized as benign, borderline, or malignant. Treatment typically involves complete surgical excision with wide margins. Adjuvant ra...
Mamatha Chivukula
Mamatha Chivukula
Features and applications of Ehrlich tumor model in cancer studies: a literature review [0.03%]
Ehrlich腹水癌模型的特征及其在肿瘤学研究中的应用价值：文献回顾
Débora Rasec Radulski,Maria Carolina Stipp,Claudia Martins Galindo et al.
Débora Rasec Radulski et al.
Background and objective: Breast cancer is the most prevalent cancer worldwide, responsible for a large number of deaths, especially among women. Therapeutic options for breast cancer include surgery, radiotherapy, chemot...
Types and progress of clinical trial design for breast cancer: a narrative review [0.03%]
乳腺癌临床试验设计的类型及进展：叙述性回顾
Teng Zhou,Jian Zhang
Teng Zhou
Background and objective: In recent years, the field of breast cancer diagnosis and therapy has witnessed rapid technological advances. Concurrently, the emergence of molecular biology and novel detection methodologies ha...
Edibaldo Silva,Steven Meschter,Mona P Tan
Edibaldo Silva
Breast cancer is a disease of global concern, regardless of economic status. A significant disparity in breast cancer care between low- and high-income countries is not unexpected, but consideration can be given to particular aspects of the...
Narrative review on the role of immunotherapy in early triple negative breast cancer: unveiling opportunities and overcoming challenges [0.03%]
免疫疗法在早期三阴性乳腺癌中的作用述评：揭示机遇和克服挑战
Keyang Qian,Qiang Liu
Keyang Qian
Background and objective: Triple negative breast cancer (TNBC) represents a highly aggressive breast cancer subtype, historically managed with chemotherapy regimens predominantly involving anthracyclines and taxanes, yiel...
Navigating next-generation HR+/HER2- metastatic breast cancer therapies: a critical commentary on abemaciclib vs. tucidinostat after palbociclib progression [0.03%]
下一代HR+/HER2-转移性乳腺癌疗法的导航：对帕博西尼进展后的阿贝西利与土莫西明的关键评论
Patrick Neven,Lieke Dullens,Sileny Han et al.
Patrick Neven et al.
Clinical considerations for estrogen receptor-negative/progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer [0.03%]
雌激素受体阴性/孕激素受体阳性/HER2阴性(bR-PR+HER2-)乳腺癌的临床考虑因素
Bruno Henrique Rala de Paula,Susanne Crocamo,Jose Bines
Bruno Henrique Rala de Paula
Hannah Hackbart,Xiaojiang Cui,Jin Sun Lee
Hannah Hackbart
Breast cancer is a heterogeneous group of diseases characterized by diverse subtypes. Currently, the classification of breast cancer is based on the status of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth fa...